Xencor, Vir partner on COVID-19 antibodies research

By The Science Advisory Board staff writers

March 27, 2020 -- Biopharmaceutical companies Xencor and Vir Biotechnology have entered into a technology licensing agreement to develop potential antibody-based treatments for patients with COVID-19.

Under the agreement, Vir will receive nonexclusive access to Xencor's Xtend Fc technology that extends the half-life of antibodies. Vir will also be responsible for costs and activities pertaining to research, development, regulatory, and commercial actions.

The two companies previously partnered in 2019 on developing and commercializing antibodies for influenza and hepatitis B infections.

Copyright © 2020 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here